Umeclidinium bromide

Umeclidinium bromide
Clinical data
Trade names Incruse Ellipta
  • US: C (Risk not ruled out)
Routes of
Inhalation (DPI)
ATC code R03BB07 (WHO)
R03AL03 (WHO) (+vilanterol)
Legal status
Legal status
Pharmacokinetic data
Protein binding ~89%[1]
Metabolism Hepatic (CYP2D6)
Biological half-life 11 hours
Excretion Feces (58%) and urine (22%)
Synonyms GSK573719A
CAS Number 869113-09-7
PubChem (CID) 11519069
ChemSpider 9693857
ECHA InfoCard 100.166.375
Chemical and physical data
Formula C29H34BrNO2
Molar mass 508.49 g/mol
3D model (Jmol) Interactive image

Umeclidinium bromide (trade name Incruse Ellipta, GSK) is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[1] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol).[2][3]


  1. 1 2 "Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Retrieved 22 February 2016.
  2. Feldman, GJ; Edin, A (2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: Current evidence and future prospects". Therapeutic advances in respiratory disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.
  3. "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
This article is issued from Wikipedia - version of the 3/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.